Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients
Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
1. To evaluate the toxicity and safety of a combination of arsenic trioxide with ascorbic
acid and high-dose Melphalan in patients with multiple myeloma
2. To evaluate the efficacy of a combination of arsenic trioxide with ascorbic acid and
high-dose Melphalan in patients with multiple myeloma
3. To determine the effects of arsenic trioxide on melphalan pharmacokinetics